We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+34.12%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$73.8M
AUM Growth
+$28.4M
Cap. Flow
+$17.1M
Cap. Flow %
23.17%
Top 10 Hldgs %
55.69%
Holding
77
New
37
Increased
5
Reduced
25
Closed
2

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$1.64M
2
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$1.49M
3
IMMU
Immunomedics Inc
IMMU
+$1.01M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$713K
5
INSM icon
Insmed
INSM
+$698K

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$870K
2
BIIB icon
Biogen
BIIB
+$320K
3
EXEL icon
Exelixis
EXEL
+$233K
4
IONS icon
Ionis Pharmaceuticals
IONS
+$141K
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$130K

Sector Composition

Rank Sector Weight
1 Healthcare 57.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
76
Biogen
BIIB
$30B
– –
-1,062
Closed -$320K
LOXO
77
DELISTED
Loxo Oncology, Inc
LOXO
– –
-6,210
Closed -$870K
1 2 3
4

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q1 2019 Portfolio in Review

As of Q1 2019, Opus Point Partners Management held 77 positions worth $73.8M, up 62% from $45.4M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management deployed $17.1M of net new capital in Q1 2019, opening 37 new positions and adding to 5 existing holdings. Its largest new stake was Bristol-Myers Squibb: 33,000 shares worth $1.57M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 50% a quarter earlier.

On the sell side, the largest reduction was Exelixis, an estimated $233K trimmed.

  • Opus Point Partners Management's largest Q1 2019 buy was Bristol-Myers Squibb: 33,000 shares worth $1.57M.
  • Opus Point Partners Management added most to Direxion Daily S&P Biotech Bull 3X ETF in Q1 2019, an estimated $1.49M increase.
  • Opus Point Partners Management's biggest Q1 2019 reduction was Exelixis, cutting an estimated $233K.
  • Opus Point Partners Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $870K.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $73.8M portfolio in Q1 2019.
  • Opus Point Partners Management opened 37 new positions and closed 2 in Q1 2019.
  • Opus Point Partners Management's portfolio value rose 62% quarter-over-quarter to $73.8M.

Based on Opus Point Partners Management's 13F filing for Q1 2019, filed 15 May 2019.